SCHEMBL23218680

SCHEMBL23218680

CCOC(=O)Cc1cccc(C)c1OCc1coc2ccc(Br)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.41
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 3/20 0.38
THRA P10827 1/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MTNR1A P48039 1/20 0.36
TP53 P04637 1/20 0.36
ALOX5 P09917 1/20 0.36
MAOA P21397 2/20 0.36
MAOB P27338 2/20 0.36
PTGER1 P34995 1/20 0.35
FFAR1 O14842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853258 1.00 THRB (0.41) THRBMEN1POLBGAAKMT2A
SCHEMBL29853198 0.90 ALOX5 (0.38) THRBMEN1POLBGAAKMT2A
SCHEMBL29593139 0.90 MEN1 (0.37) THRBMEN1POLBGAAKMT2A
SCHEMBL23218492 0.90 MEN1 (0.37) THRBMEN1POLBGAAKMT2A
SCHEMBL23218199 0.90 ALOX5 (0.38) THRBMEN1POLBGAAKMT2A
SCHEMBL23218128 0.89 MAOB (0.40) MEN1POLBGAAKMT2AMAPT
SCHEMBL29852717 0.89 MAPT (0.40) THRBMEN1POLBGAAKMT2A
SCHEMBL23218697 0.89 MAPT (0.40) THRBMEN1POLBGAAKMT2A
SCHEMBL29852861 0.89 MAOB (0.40) MEN1POLBGAAKMT2AMAPT
SCHEMBL23218939 0.89 NPC1 (0.36) THRBMEN1POLBGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB THRB 2013/4885MEN1 1819/4885POLB 3530/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB THRB 3892/4885MEN1 548/4885POLB 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.